Science Allergy

Main idea: The ARPhyS scale seems the best method to target patients with severe seasonal allergic rhinitis. In the present study optimal discrimination cut-offs were highlighted. This tool could be implemented in a daily practice to identify severe patients who need a specialized intervention. Abstract Allergic rhinitis (AR) is a chronic disease affecting a large […]

Main idea: This study confirmed both the clinical efficacy and safety of a sublingual liquid birch pollen extract in adults with birch pollen allergy in a pivotal phase III trial. Abstract Background: Sublingual allergen immunotherapy (SLIT) has been demonstrated to be both clinically efficacious and safe. However, in line with the current regulatory guidance from […]

Main idea: Triamcinolone acetonide proved to be non-inferior to fluticasone propionate in adult patients with perennial allergic rhinitis; both treatments decreased rhinitis symptoms and showed a good safety profile. Abstract Intranasal sprays are recommended as targeted therapy for allergic rhinitis (AR). Triamcinolone acetonide is a nasal corticosteroid preparation indicated for the treatment of seasonal and […]

Main idea: Although the primary endpoint was not reached for the Full Analysis Set, a significant and clinically relevant effect on Symptom Medication Score was clearly demonstrated for the subgroup of patients in the northeastern region of Europe, where birch is the predominant tree species. Proving efficacy of birch allergen subcutaneous immunotherapy is challenging due […]

Main idea: MP-AzeFlu was superior to AZE in reducing moderate-to-severe seasonal allergic rhinitis symptoms, providing earlier and better symptom relief. Abstract The novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in a single spray (MP-AzeFlu) was compared with a first-line intranasal antihistamine spray (AZE) in Russian seasonal allergic rhinitis (SAR) patients. Moderate-to-severe […]

Main idea: Seven-dose treatment and four-dose treatment of allergic rhinitis are comparable in terms of safety and tolerability. Abstract The aim of the study was to investigatesubcutaneous immunotherapy efficiency in treating allergic rhinoconjunctivitis and asthma but is still inconvenient when heavy schedules are used. In this open-label, Phase II trial, 130 adults were randomized 1:1 […]

Main idea: Having asthma or an atopic disease during childhood or adolescence does not negatively impact academic performance. This information can be used by clinicians when talking with children and parents about the implications of living with asthma or atopic disease. Abstract Over a fifth of children and adolescents suffer from asthma or atopic disease. […]

Main idea: The safety profile of 5-grass tablet in pediatric allergic rhinitis patients aged 5 to 9 years was consistent with safety findings in older patients. Abstract Although 5-grass pollen sublingual immunotherapy has a good safety profile in controlled clinical trials, additional safety information among pediatric patients in a real-world setting would be useful. The […]

Main idea: GSP301 was efficacious and well-tolerated for the treatment of seasonal allergic rhinitis symptoms compared with placebo, with a rapid onset of action of 15 minutes in patients aged ≥12 years. Abstract GSP301 is an investigational fixed-dose combination nasal spray that contains the antihistamine, olopatadine hydrochloride (HCl), and the corticosteroid, mometasone furoate. The objective […]

Abstract The safety and efficacy of GSP301 nasal spray, an investigational fixed-dose combination of olopatadine hydrochloride and mometasone furoate, were established in three large 2-week seasonal allergic rhinitis studies. The objective of the study was to evaluate long-term (52 weeks) safety and efficacy of GSP301 in patients with perennial allergic rhinitis (PAR). In this randomized, […]